Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/21645515.2020.1787074 http://scihub22266oqcxt.onion/10.1080/21645515.2020.1787074 32678695!7872068!32678695     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Hum+Vaccin+Immunother 2021 ; 17 (1): 84-87 Nephropedia Template TP {{tp|p=32678695|t=2021. Neutralizing and cross-reacting antibodies: implications for immunotherapy and SARS-CoV-2 vaccine development |pdf=|usr=}}{{32678695}} gab.com Text Neutralizing and cross-reacting antibodies: implications for immunotherapy and SARS-CoV-2 vaccine development JO: Hum Vaccin Immunother http://www.kidney.de/pget.php?&tw=1&pmid=32678695 #FOAvip The novel coronavirus SARS-CoV-2 emerged in China in 2019 and quickly spread globally, causing a pandemic. There is an urgent need to develop vaccines against the virus, and both convalescent plasma and immune globulin are currently in clinical trials for treatment of patients with COVID-19. It is unclear whether antibodies induced by SARS-CoV-2 have neutralizing capacity and whether they can protect from future infection. Seasonal human coronaviruses (HCoV) have been circulating for decades. It is currently unknown whether antibodies against seasonal HCoV may cross-neutralize SARS-CoV-2. Data from neonates suggest that trans-placental antibodies against HCoV may have neutralizing capacity. Here we briefly review the epidemiologic observations on HCoV and discuss the potential implications for neutralizing and cross-neutralizing antibodies against SARS-CoV-2. Twit Text FOAVip Neutralizing and cross-reacting antibodies: implications for immunotherapy and SARS-CoV-2 vaccine development ????Hum Vaccin Immunother http://www.kidney.de/pget.php?&tw=1&pmid=32678695 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32678695 #FOAvip English Wikipedia <ref>{{Cite pmid|32678695}}</ref> Neutralizing and cross-reacting antibodies: implications for immunotherapy and SARS-CoV-2 vaccine development #MMPMID32678695 Cohen SA; Kellogg C; Equils O Hum Vaccin Immunother 2021[Jan]; 17 (1): 84-87 PMID32678695show ga The novel coronavirus SARS-CoV-2 emerged in China in 2019 and quickly spread globally, causing a pandemic. There is an urgent need to develop vaccines against the virus, and both convalescent plasma and immune globulin are currently in clinical trials for treatment of patients with COVID-19. It is unclear whether antibodies induced by SARS-CoV-2 have neutralizing capacity and whether they can protect from future infection. Seasonal human coronaviruses (HCoV) have been circulating for decades. It is currently unknown whether antibodies against seasonal HCoV may cross-neutralize SARS-CoV-2. Data from neonates suggest that trans-placental antibodies against HCoV may have neutralizing capacity. Here we briefly review the epidemiologic observations on HCoV and discuss the potential implications for neutralizing and cross-neutralizing antibodies against SARS-CoV-2. |Antibodies, Neutralizing/immunology[MESH] |Antibodies, Viral/*immunology[MESH] |COVID-19 Vaccines/immunology/*therapeutic use[MESH] |China[MESH] |Female[MESH] |Humans[MESH] |Immunotherapy/*methods[MESH] |Pregnancy[MESH]Neutralizing and cross-reacting antibodies: implications for immunothe(epmc).pdf DeepDyve Pubget Overpricing